Streptomyces hygroscopicus subsp. aureolacrimosus SANK60286 and SANK60576 produce many kinds ofmilbemycins. Amongthem, milbemycin all5 a14, A3, and A4 have the most effective acaricidal activity. In this study, we investigated the terminal biosynthetic pathway to milbemycin a14 and A4 which accumulated as the final products in these strains. Using cerulenin, a specific inhibitor of fatty acid and polyketide biosynthesis, we conducted bioconversion experiments with cultures of several mutants, including milbemycin A4-and a14-producing strains. The byconversions of milbemycin /?6 to milbemycin A4 and milbemycin A4 to milbemycin a14 could be identified. For the biosynthesis of milbemycin A4 from milbemycin /?6 in the milbemycin A4-high producing strain, there appeared to be two separate pathways exhibiting different sequences of furan ring formation and C-5 keto reduction steps.
Since the discovery in 1967 ofB-41, a metabolite with an outstanding activity against various kinds of mites, more than 30 kinds of structurally similar milbemycins have been isolated from a fermentation broth of the Streptomyces hygroscopicus subsp. aureolacrimosus1]'.
Researchers at Sankyo Co., Ltd. elucidated the structure of milbemycins using X-ray crystallographic analysis of the /?-bromophenyl-urethane derivative, mass spectrometry, and XH and 13C NMRspectroscopy2). The structure was basically a 16-memberedlactone with a spiroketal ring system consisting of two six-membered In biosynthetic studies, it was reported that the macrolide ring of milbemycins was biosynthesized via a polyketide derived from the condensation of several units of acetate, propionate, and a branched chain fatty acid3). For avermectins,. the clustered genes encoding the biosynthetic enzymes have been cloned and the biosynthetic order of avermectins after the formation of 16-membered macroeyclic lactones has been studied4~7). However, further study of the biosynthetic pathway of milbemycins has been limited to an investigation of the pathway from milbemycin J and K to A3 and A4 using an intact-cell and cell-free system of the strain Rf-1078).
Cerulenin is a specific inhibitor of the condensation reaction in the biosynthesis of fatty acids and polyketides with no effect on the growth of those producing microorganisms9).
During a screening program for isolating a high-producing strain of milbemycins, we obtained several improved strains and blocked mutants.
These strains enabled us to study the biosynthetic sequence of various milbemycins under conditions that allowed cerulenin to inhibit the formation of the macrolide ring. In this paper, we report a bioconversion study conducted with cerulenin to deduce the terminal biosynthetic pathway ofmilbemycins including milbemycin A4 and a14.
Materials and Methods

Microorganisms
During a screening program of high producing milbemycin strain, some blocked mutants were isolated by means of mutagen treatment and monospore isolation (Table 1) . Each strain was maintained on 1/2YMslant agar (sucrose 0.4%, skim milk 0.1%, yeast extract 0.2%, malt extract 0.5%, agar 2.0%, pH 7.2) at 28°C or in 50% (W/V) glycerol solution at -20°C. FEB. 1999 Preparation of Milbemycin-related Compounds The structure of the compoundsused for byconversion is shown in Fig. 1 was isolated and purified by silica gel chromatography and preparative HPLC.This structure was determined in comparisonwith other milbemycinstructures after some analyses (data not shown).
Fermentation and Bioconversion
Spore suspension was inoculated into PS medium (sucrose 1.0%, Polypepton 0.35%, K2HPO4 0.05%, pH 7.2) and cultured for 3 days at 28°C on a rotary shaker. Next, 1 ml of seed culture was transferred into a 100ml To analyze converted product in the culture broth, 0.5 ml of the broth was mixed with 4.5 ml of MeOHand sonicated for 20 minutes. Ten /A of the filtered solution A PCV of cerulenin-added culture, A PCV of control culture, <> productivity of cerulenin-added culture, aefproductivity of control culture. 
Effect of Cerulenin on Milbemycin Production
Milbemycin production of strain RM28D-688,milbemycin an/a^-producing strain, was not affected when cerulenin was added at the beginning of cultivation, but it was inhibited strongly when cerulenin was added to the culture broth every 24 hours. Figure 2 shows the time course of milbemycin alx and a14 production with or without cerulenin. In the cultivation with addition of 25/zg/ml of cerulenin every 24 hours for lldays, small amounts of milbemycin an and a14 were detected by HPLC analysis from day 3, and its production was inhibited to 40% of the control culture. In case over 25 //g/ml ofcerulenin was added to the culture broth, the growth of tested strain was unstable and no bioconversions were occurred. Wealso confirmed that the successive addition of 25 jiglvnl of cerulenin inhibited milbemycins production of other strains used for the following bioconversion tests (data not shown). Therefore, we set up the experimental conditions for bioconversion as indicated in Materials and Methods.
The bioconverted product was determined by comparing with the control culture (with cerulenin, without milbemycins) as shown in Fig. 3 .
Bioconversion of 25-Ethyl Milbemycin-related
Compounds by Strain RDGr Strain RDGrproduced milbemycin A3 and A4 as major products. Milbemycin fi6 added into the cerulenin-supplemented culture of strain RDGr was converted to milbemycin A4. Milbemycin K, /?5, and /?4 were also converted to milbemycin A4 under the same conditions, but milbemycin a27 was not converted to milbemycin a14 (Fig. 3. and Table 2 ).
Compounds Milbemycin /J4 was converted to milbemycin fi2 and unknown products under the same conditions, but milbemycin f}5 was not converted ( and Table 2 ).
Byconversion of 25-Ethyl Milbemycin-related
Compounds by Strain M28D-10/82
Strain M28D-10/82 derived from milbemycin outproducing strain produced four milbemycin-related compounds, /?1? /?2, B2, and B3, as major products.
Milbemycin K, A4, and a27 were converted to milbemycin A4, B3, and a14, respectively. Milbemycin /?5 was converted to milbemycin fi2 via jS4 under the same conditions (Table 2) .
after, and 24 hours after the addition of milbemycin-113 Bioconversion of Milbemycin A4 by Strain 57-338
Strain 57-338 derived from milbemycin a14-producing strain produced milbemycin B2, B3, and a27 as major products. Milbemycin A4 was converted to milbemycin a27 and B3 by strain 57-338 (Fig. 4. and Table 2 ).
Bioconversion of C-25 Ethyl Milbemycin-related
Compounds by Strain BC-5-55
Strain BC-5-55 derived from milbemycin a14-producing strain produced milbemycin fi6 and p7 as major products. The bioconversion of milbemycin K to a27 via A4, milbemycin A4 to a14 via a27, milbemycin a27 to a14, and milbemycin /?4 to /?2 were respectively confirmed, but milbemycin fi5 was not converted (Table   2) . HPLC traces A, B, C, and D recorded 0 hour, 1 week, 2 weeks, and 3 weeks after the extraction of milbemycin-related compounds from culture broth.
Conversion of Milbemycin /?6 in MeOH Milbemycin fi6 was ordinarily converted to milbemycin A4 via fi5 and /?4, or via milbemycin K by milbemycin-producing strain. WhenMeOHextract containing milbemycin /?6 was kept at room temperature, milbemycin fi6 was converted to a new compound, 25-ethyl milbemycin /?3 (Fig. 5) .
Discussion
Cerulenin is a powerful inhibitor useful in analyzing the biosynthetic sequence after the formation of polyketide or macrolide compounds. To elucidate the biosynthetic pathway of milbemycin a14 from milbemycin fi6 and the mutated steps in several blocked mutants, we examined bioconversions with cerulenin added to the culture broth. The results of bioconversion by using strains Rf-107 and RDGr,suggest that there are two FEB. 1999 routes for furan ring formation leading to milbemycin A4, one is milbemycin /?6->/?5-»/?4-»A4 and the other is /?6-»(X)-»K->A4.
In strain Rf-107, one of furan ring formation (milbemycin /?6-»(X)->K) was working but the other (milbemycin /?4->A4) was not. Wethink there would be two enzymes, which had different substrate specificities, and an intermediate X, C-8a hydroxyl milbemycin /?6, which has not yet been isolated in the culture broth, existed in the pathway of milbemycin fi6
to K. This compound might be unstable and quickly converted to milbemycin K in the culture broth of our milbemycin producer. Although the producing organism is different from ours, the corresponding compoundto intermediate X, VM44868, has been already isolated and reported by SmithKline Beecham group10). VM44868 would be bioconverted to a-type milbemycin, VM44857, in the culture broth by the similar reaction, equivalent to the steps V and VI in Fig. 6 . On the other hand, milbemycin jS6 is non-enzymatically converted to 25-ethyl milbemycin /?3 in MeOH as shown in Fig. 5 . The corresponding compound to 25-ethyl milbemycin /?3, VM54339, would be also non-enzymatically converted from VM44868 in MeOH. According to the report by H. Ikeda and S. Omura11}, it has shown that the oxygen in the benzofuran between C-6 and C-8a is derived from molecular oxygen, and this oxdation would be performed by cytochrome P450 type oxidase. By isolating BC-5-55, a strain which accumulated milbemycin fi6 and /?7, wedetermined that the first formed of the 25-ethyl milbemycins was milbemycin f$6. In addition, the results of bioconversion by using strain BC-5-55, suggest that there would be two enzymes for C-5 keto reduction in the two routes from milbemycin /?6 to A4. In strain BC-5-55, one of deduced C-5 keto reductase (milbemycin K->A4) was working but the other 0S6->/?5) was not. From these bioconversion tests, the plausible biosynthetic pathway from milbemycin fj6, the first formed product, via a hypothetical polyketide derived from 7 acetate and 6 propionate units, is summarized in Fig. 6 .
The blocked steps in the tested strains are also indicated in the Figure. These two biosynthetic pathways exclusively demon- 
